- This narrative practical review synthesizes indirect pharmacological and adjacent procedural evidence, with no dedicated comparative trial of local anesthetics within RFA.
- It suggests lidocaine 1% as a default for skin and track anesthesia, and avoiding lidocaine 2% near the target nerve where stimulation testing is done, based on mechanistic reasoning.
- Across five randomized trials outside interventional pain settings, premixing lidocaine and bupivacaine showed no onset advantage over bupivacaine alone and sometimes shortened duration.
- The authors conclude these considerations are provisional and call for prospective studies, and they provide an allergy substitution pathway centered on formal allergist evaluation.
Chronic pain
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Single-center retrospective pilot cohort of 58 adults with a previously implanted spinal cord stimulator who underwent non-SCS spine surgery between 2016 and 2026.
- Documented perioperative management was benchmarked against prespecified elements: preoperative deactivation or surgery mode, and electrocautery approach (bipolar, or monopolar with the generator contralateral to the return pad).
- Alignment was 13.8% (95% CI, 7.2 to 24.9) for deactivation or mode and 43.1% (95% CI, 31.2 to 55.9) for electrocautery, with only 3.4% (95% CI, 1.0 to 11.7) meeting both.
- Five cases (8.6%; 95% CI, 3.7 to 18.6) had device-related adverse events, including one generator failure after monopolar cautery with an undocumented return-pad location; the authors call for prospective study of structured protocols.
- Systematic review and meta-analysis of 67 double-blind, placebo-controlled studies in healthy volunteers (N = 2706) testing acute peripheral pain.
- Compared centrally active opioid antagonists with placebo during pain testing, using a three-level random-effects meta-regression across intensity, tolerance, unpleasantness, and threshold.
- Mu-opioid blockade was associated with slightly higher pain than placebo (Hedges' g = 0.18, 95% CI 0.11 to 0.25), about 2.8 points on a 0-100 scale; I² was 66%.
- Reporting bias likely overestimated the effect, and study characteristics explained little heterogeneity; the authors conclude endogenous opioids play a minor role in human acute pain regulation.
- Cross-sectional controlled study at a single Turkish centre comparing 59 women with lipedema against 59 age-matched healthy controls.
- Lipedema patients were assessed against controls on pain intensity, neuropathic features, central sensitization symptoms, catastrophizing, sleep, quality of life, and pressure pain thresholds.
- Lipedema patients scored worse on pain, central sensitization, catastrophizing, and sleep disturbance, and had lower pressure pain thresholds and SF-36 scores (all p < 0.001); 78.0% versus 8.5% met the CSI ≥40 threshold.
- The authors conclude that lipedema pain extends beyond local adipose changes and supports a multidimensional approach to pain assessment.
- Descriptive review of 288 neuropathic pain RCTs of pharmacotherapy and neuromodulation, of which 36 (12.5%) reported a blinding assessment.
- The 37 studies with a blinding assessment were mostly crossover (19) or parallel (17) designs; all assessed participant blinding, and 10 also assessed investigators.
- Using the Bang Blinding Index in 17 trials, 10 of 17 placebo and 10 of 17 treatment arms remained blinded (BI = 0 ± 0.2).
- The authors conclude that blinding assessments are uncommon and methodologically variable, and they call for consensus on how to conduct and interpret them.
- Retrospective cohort at two affiliate hospitals (2015-2026) of eight patients with a pre-existing spinal cord stimulator, covering 12 deliveries.
- Neuraxial labor analgesia or cesarean anesthesia was attempted in every delivery, with the cohort including both successes and failures.
- A reportedly successful block was achieved in 10 cases, both failures occurred in emergencies, and no dural puncture, new deficit, LAST, ICU admission, or device complication was recorded.
- Intrapartum device status was documented in only three of 12 deliveries, so the authors conclude that peripartum device management was inconsistently documented.
- Single-patient case report of a woman in her late 20s with refractory post-traumatic chronic pain, PTSD, headaches, and occipital neuralgia after repeated traumatic brain injuries.
- She received an ultrasound-guided percutaneous temporary left vagus nerve stimulator for 60 days after conservative management failed.
- Pain fell from 10/10 to 0/10 over eight weeks, and the analgesic benefit was reported as sustained at 4-month follow-up.
- PCL-5 PTSD scores rose during follow-up, and no pre-procedure PCL-5 baseline was available to judge the overall change.
- This preclinical study used a rat post-cast immobilization model of disuse pain and compared male and female animals.
- Rats received the antioxidant Tempol after immobilization, with outcomes measured behaviorally and through peripheral, spinal, and amygdala markers.
- Tempol reduced mechanical hyperalgesia in both sexes, but only males developed tactile and cold allodynia, and females never developed tactile allodynia.
- Males showed raised pro-inflammatory cytokines in the soleus muscle while females showed blunted inflammation, which the authors link to sex-dependent tactile allodynia.
- Longitudinal study of 285 people undergoing primary total knee arthroplasty, with five assessments from preoperative baseline to 1 year.
- Random-intercept cross-lagged panel models tracked within-person changes in knee-specific body perception (FreKAQ) and pain intensity on 100-mm visual analogue scales.
- Higher FreKAQ scores at 6 months were associated with greater pain at 1 year for movement pain (β = 0.262, P = 0.004) and resting pain (β = 0.359, P = 0.003).
- Resting pain at 3 months was associated with later FreKAQ scores (β = 0.179, P = 0.033), while the authors found no other significant pain-to-body-perception paths and note the findings do not establish causality.
- Prospective observational cohort of 171 patients at one center undergoing spinal cord stimulation trials (2017–2021), comparing screening-based fast track with formal psychological assessment.
- Patients who screened negative on validated questionnaires and a mental health checklist went straight to trial (FT), while screen-positive patients saw a psychologist (AP).
- Trial-to-implant rates were similar (72% AP vs 70% FT, p=0.811), and 1-year responder rates were comparable (53% AP vs 60% FT, p=0.927).
- Higher baseline pain intensity and tricyclic antidepressant use were associated with implant failure, while pain duration over 10 years was associated with success; the authors conclude the tool allows bypassing routine assessment without compromising outcomes.
- Randomized, placebo-controlled, double-blinded crossover-style study in 20 healthy participants testing topical drugs on peripheral sensory nerve excitability.
- Compared topical 5% lidocaine, 10% phenytoin and 2% mepyramine against placebo, measuring perception threshold changes with a new sodium channel nociceptor testing protocol.
- Perception threshold increases differed between drugs (P < 0.01) and versus placebo (P < 0.01), except phenytoin (P = 0.22), which did not differ significantly.
- Authors report a computational model suggesting lidocaine and mepyramine alter Nav1.7, 1.8 and 1.9 currents differently, supporting the protocol for probing subtype-specific pharmacology.
- Prospective cohort of 87 adults with primary hemifacial spasm receiving botulinum toxin type A at a tertiary referral center, followed for 4 months.
- Facial pain was characterized with a questionnaire, Visual Analog Scale, McGill Pain Questionnaire, pain diary, and anxiety/depression scale, and tracked after treatment.
- Facial pain was present in 40.2% of patients, mostly periorbital (77.1%), and was independently linked to female sex (OR 3.47, 95% CI 1.00-11.97; p = 0.049) and subjective disease burden (OR 1.01, 95% CI 1.00-1.03; p = 0.034), not motor severity.
- Although 88.2% reported subjective improvement after treatment, objective pain measures did not change, and the authors recommend routine facial pain assessment in HFS.
- Retrospective single-center cohort of 22 patients (16 cervical, 6 thoracic) who had SPECT/CT, dual medial branch blocks, and RFA between January 2023 and May 2025.
- Compared outcomes across SPECT/CT-RFA concordance subgroups; imaging was at physician discretion, so there was no non-SPECT/CT control arm.
- At first follow-up, 16/18 (89%) met the NRS MCID and 7/13 (54%) met the MODI MCID; concordance comparisons were underpowered, with wide confidence intervals.
- Authors report clinically meaningful pain reduction across all concordance categories and suggest SPECT/CT may complement planning, pending larger prospective studies.
- Retrospective chart review of 105 cervical transforaminal injections or selective nerve root blocks in 95 patients at one tertiary academic center.
- Antithrombotic therapy was continued for 25 procedures and interrupted for 80, and complications were compared between groups over 0 to 30 days.
- No hemorrhagic complications occurred in either group; ischemic events were 1/25 (4.0%) with continuation and 2/80 (2.5%) with interruption, p = 0.562.
- The authors describe the findings as mainly descriptive because of the small sample and few events, not definitive evidence of procedural safety or comparative ischemic risk.
- This overview reviews health economic principles and published full and partial economic evaluations of intrathecal drug delivery (ITDD) systems across cancer pain, chronic non-cancer pain, and spasticity.
- ITDD is compared with conventional management strategies, and the analyses span varying perspectives and healthcare settings.
- Most analyses suggest ITDD is cost-effective, particularly for cancer-related pain and spasticity, though the authors caution that findings rest on heterogeneous methods and often small or uncontrolled effectiveness data.
- Evidence for chronic non-cancer pain is sparse and inconsistent, and the authors call for comparative effectiveness research and long-term economic modeling.
- This case report describes one patient with prior lumbar spine surgery and refractory low back pain who had two intrathecal pump explants for suspected infection.
- The patient was ultimately diagnosed with type IV titanium hypersensitivity, and the pump was reimplanted after being encased in an expanded polytetrafluoroethylene (ePTFE) fabric pouch.
- The reimplanted intrathecal drug delivery system was reported as successful, with no rejection described.
- The authors conclude that device-component hypersensitivity should be considered in recurrent or unexplained pump site complications, and that an ePTFE pouch may allow reimplantation.
- A retrospective single-center study of 53 patients with refractory cancer pain on intrathecal infusion systems, where the sequential flex mode was used after continuous mode failed.
- The sequential flex mode uses a basal flow with large boluses and was compared with the prior continuous flow rate mode in the same patients.
- 71.7% ± 6.43% of patients achieved at least 30% NRS reduction, and median NRS fell from 6.4 (SD 2.0) to 3.3 (SD 2.2), p<0.0001.
- The authors conclude the flex mode may improve pain relief and limit dose escalation, with adverse effects in 20.3% of switches, mostly non-serious increased anxiety.
- This practical guide synthesizes evidence, consensus recommendations, and international clinical experience on intrathecal drug delivery for refractory pain.
- It covers preimplant evaluation, trialing, pump and catheter selection, perioperative care, early troubleshooting, long-term maintenance, and complication surveillance.
- It reviews intrathecal opioids, local anesthetics, ziconotide, clonidine, and baclofen, with attention to indication-specific dosing and safety, but reports no pooled quantitative results.
- It frames outcomes beyond pain intensity, including function, quality of life, and reduced systemic medication use, and addresses cancer and non-cancer populations separately.
- Retrospective single-center study of 215 patients with chronic non-cancer pain who received intrathecal drug delivery devices between 2009 and 2022, most with PSPS2 (184 patients).
- The exposure was intrathecal drug delivery, and explant reasons were compared with spinal cord stimulation explant rates from a similar patient population.
- The explant rate was 26.1%, with device-related infection the leading cause in 9.3% of patients (5.9% of device surgeries) and loss of analgesic efficacy in 5.6%.
- Infections occurred earlier after implant than other complications, and no demographic or comorbidity factors correlated with explant, per the authors.
- Single-center retrospective chart review of 441 cancer patients with intrathecal pumps, of whom 117 had two chest CTs at least 30 days apart.
- No comparator; catheter migration was defined as movement of one or more vertebral levels between the two imaging studies.
- Migration occurred in 15.4% (18 of 117), all limited to a single level; revision-requiring migration occurred in 2 of 441 (0.45%).
- The authors conclude minor migration is common but clinically significant migration is rare with their anchoring and closure techniques, and no demographic factors were associated.
- Retrospective case series of five patients with chronic pain and regionally localized pain who had implanted intrathecal devices and received bupivacaine monotherapy.
- Device duration ranged from over 2 to over 12 years, and two patients had moved from an opioid-bupivacaine combination to bupivacaine alone.
- All five patients reported at least 50% pain relief and stopped systemic opioids.
- The authors suggest monotherapy may be effective for localized pain but state that more studies are needed to establish its safety and efficacy.
- A single-center retrospective study of 31 patients, with 162 serial blood samples drawn before pump refills during intrathecal bupivacaine for cancer pain.
- Serum bupivacaine concentration was examined against daily dose and infusion flow rate, with body mass index also assessed as a factor.
- Mean serum concentration was 167.7 µg/L (SD 266.2) at a mean daily dose of 39.5 mg/day (SD 31.4), and concentration rose with dose.
- Higher flow rates stayed independently associated with concentration after adjusting for dose, and the authors conclude exposure is well below the toxicity threshold.
- This narrative review searched five databases and screened studies with three reviewers, then synthesized them descriptively due to heterogeneity.
- It examines intrathecal drug delivery systems for less common refractory pain, including spinal cord injury pain, transverse myelitis, diabetic neuropathy, postherpetic neuralgia and craniofacial pain.
- The authors found the evidence rests mainly on observational studies and small trials, with possible meaningful relief in selected patients but variable magnitude and durability of response.
- They conclude the evidence is limited, that selective clinical use may contribute to this gap, and that future research is needed to define its role.
- Retrospective single-center cohort of 435 patients with cancer pain treated with intrathecal drug delivery from 2013 to 2023; 222 met inclusion criteria.
- Longitudinal Brief Pain Inventory and Condensed Memorial Symptom Assessment Scale scores were compared before and after implantation, with no concurrent comparator group.
- Over the first 90 days, pain severity, pain interference, and physical symptom scores each declined per day (BPI-SEV -0.014, 95% CI -0.020 to -0.009; BPI-INT -0.020; CMSAS-PHYS -0.004), and 91% stopped systemic opioids.
- Scores worsened before implantation and improved afterward, and the authors report benefits sustained up to one year.
- Systematic review and meta-analysis of 39 studies (n=2652) in adults with chronic non-cancer pain treated with intrathecal drug delivery.
- Twenty single-arm comparisons contributed to the pain-intensity meta-analysis at 12 months, so there was no controlled comparator.
- Pooled pain reduction from baseline was 2.64 (95% CI 2.19 to 3.08), with a 75% probability of exceeding the 2-unit MCID (95% CI 68% to 83%).
- All studies reported functional and HRQoL improvements, but adverse event reporting was inconsistent and certainty of evidence was low.
- In 42 healthy volunteers receiving fluctuating noxious heat, researchers trained deep learning models to detect pain decreases from brief physiological signal windows.
- The models combined electrodermal activity, heart rate, pupil diameter, and other signals, with a transformer architecture performing best on a held-out test set of 9 participants.
- The best combined model reached AUROC 0.854 and accuracy 76.8%; continuous detection had median latency 5.75 seconds and 70.4% sensitivity.
- Electrodermal activity was the most informative single predictor, and the authors suggest electrodermal activity and heart rate suit practical deployment while EEG and facial expressions need personalized models.
- Preclinical mouse study of male and female mice with apical periodontitis induced by pulp exposure, compared with sham surgery, assessing mechanical hypersensitivity with von Frey filaments at day 21.
- Single oral CBD dose versus vehicle, with intrathecal, intracisternal, and intraoral CBD routes and TRPV1 antagonist AMG 517 pretreatment to probe site of action and mechanism.
- Oral CBD significantly reduced mechanical hypersensitivity at 45 and 120 minutes, with a greater effect in males than females; no numerical effect sizes or p values are given in the abstract.
- Authors conclude oral CBD is an effective analgesic for apical periodontitis-induced hypersensitivity acting centrally and involving TRPV1, based on this model.
- Two experiments (Study A n=74, Study B n=60; 134 participants total) tested unfamiliar music during thermal pain stimulation, with excerpts selected using the Arousal, Valence, Depth model.
- Musical excerpts were chosen to be high in arousal or depth, and the analysis examined how participants' pleasantness ratings related to their pain responses.
- In Study A, high-arousal music increased pain unpleasantness and high-depth music provided relief, and these effects were completely mediated by pleasantness ratings.
- Study B replicated the benefit of musical depth and found participants' perceptions aligned with AVD dimension loadings; trait systemizing moderated depth analgesia in one study.
- This qualitative study followed ten adolescents aged 12-15 with longstanding non-traumatic knee pain through two online semi-structured interviews.
- Interviews occurred 1-3 days and then 11-17 days after a clinical consultation, and were analyzed with reflexive thematic analysis and matrix analysis.
- Six key areas emerged over time, including limited recall of medical information, seeking proof, and a rigid activity-versus-rest dichotomy.
- The authors conclude that adolescents' perceptions are dynamic and that communication and self-management support should be personalized.
- In a cross-sectional study of about 950,000 Million Veteran Program participants with at least two visits, two EHR code-based phenotyping strategies were compared for 17 pain, internalizing, and opioid use conditions.
- The Multiple Code strategy, requiring one inpatient or two outpatient codes, was compared with the Any Code strategy requiring a single code.
- Multiple Code excluded 33.5% of Any Code cases on average, and the observed change in correlations (mean |Δr|=0.014) was smaller than in all 1000 random-thinning replicates.
- Both strategies supported a correlated four-factor model (CFI=0.987), and the authors conclude that the stricter definition changes case mix and prevalence but preserves the overall relationships among conditions.
- Double-blind randomized controlled trial of 115 Veterans with chronic low back pain and prescription opioid misuse (NCT02483468).
- Participants received either real or sham transcranial direct current stimulation during 11 sessions of Cognitive Behavioral Therapy for Chronic Pain.
- Real stimulation showed significant time-by-group interactions for pain and functional impairment, with a steeper decline than sham.
- Opioid misuse decreased over time in both groups with no added benefit from stimulation, and the authors describe it as a promising adjunct.
- This cohort study of Mississippi Medicaid beneficiaries (2019-2022 trends, 2021 COB cohort) compared PDMP-linked claims with Medicaid claims alone.
- Linking PDMP data with Medicaid claims was compared against Medicaid claims alone for opioid prescription identification and concurrent opioid-benzodiazepine (COB) measure reporting.
- PDMP-linked data identified more beneficiaries with opioid prescriptions (12,339 vs. 10,972, p<.001) and more concurrent users (14,067 vs. 9,344); the COB rate rose from 3.7% to 8.0%.
- Higher average daily opioid dose predicted additional concurrent-user identification, while Black race and concurrent psychotropic use predicted lower odds; the authors conclude linked data improves surveillance accuracy.
AI summary not available. Read the source abstract on PubMed.
- This preclinical mouse study examined hypersensitivity and spinal and supraspinal changes after unilateral distal bone fracture, comparing sexes and ages.
- The exposure was a unilateral distal fracture, with outcomes assessed across female and male mice of different ages.
- Contralateral hypersensitivity appeared in aging groups, earlier in females than males, and aging males showed contralateral spread of spinal network changes.
- In aging male mice, alpha-adrenergic receptors were differentially regulated on both sides of the spinal cord and locus coeruleus, which may contribute to hyperexcitability.
- This single-center observational cohort of 582 consecutive adult injections (February to June 2022) examined intraprocedural pain during fluoroscopically guided lumbar and caudal epidural steroid injections.
- Patient and procedure factors were analyzed with multivariable linear regression, and pain was compared across transforaminal, interlaminar, and caudal approaches.
- Mean intraprocedural pain was 4.57 ± 2.79 on a 0–10 scale; older age (β = -0.029, 95% CI -0.043 to -0.014, p < 0.001) and male sex (β = -0.59, 95% CI -1.05 to -0.12, p = 0.013) were linked to lower pain.
- Higher pre-procedure pain and greater injectate volume were independently linked to more intraprocedural pain, while injection approach was not, which the authors suggest should inform patient counseling.
- A retrospective propensity-matched cohort from a large global database compared adults with cervical radiculopathy codes who received CTFESI or CILESI.
- Groups were matched on demographics, comorbidities, prior opioid use, and prior spine surgery; the primary outcome was eventual anterior fusion, disc replacement, or neuroforaminotomy.
- Only directional results are given: higher surgery and opioid use after CTFESI, more stroke, seizure, MI and minor complications, and no paralysis difference.
- The authors conclude CILESI was associated with fewer opioid prescriptions, complications, and surgeries, but suggest these differences may reflect selection bias in clinician decisions.
- Cross-sectional analysis of Wave 1 of the Longitudinal Ageing Study in India, including 6382 cohabiting opposite-sex married couples aged 60 or older.
- Survey-weighted logistic models tested respondent and spouse frequent pain as correlates of the respondent's frequent insomnia symptoms, defined as occurring at least 5 nights per week.
- Respondent pain alone was associated with higher odds of frequent insomnia (OR 3.12, 95% CI 2.53-3.83), while spouse pain alone showed a smaller association (OR 1.41, 95% CI 1.11-1.79).
- Adjusted probabilities were 7.03% with no partner pain and 18.69% with respondent-only pain; the joint effect was subadditive (-5.13 points, 95% CI -8.70 to -1.56).
- This qualitative study interviewed 27 American Indian/Alaska Native adults with chronic pain using semi-structured interviews, coded by two independent coders.
- Participants generally did not see pain as a distinct adversity that would change their definition of resilience, viewing it as another hardship needing persistence, balance, and acceptance.
- Thematic analysis identified four interrelated themes: pain management and adaptation, psychological and behavioral resilience, cultural resources and practices, and system-level impacts.
- The authors propose the first model of chronic pain resilience in this population, which they describe as a foundation for future investigation and needing culturally centered interventions.
- Prospective 2-year study of 66 patients with newly diagnosed inflammatory arthritis, using patient-reported measures, ultrasound, quantitative sensory testing, and mixed-effects models.
- Exposure was baseline and longitudinal centrally mediated pain features, compared with joint inflammation assessed by ultrasound.
- Inflammation was not associated with later pain (b -0.05, P = 0.87), while higher centrally mediated scores predicted less pain reduction (b 1.41, P < 0.001).
- The authors conclude persistent pain tracked central features rather than ultrasound inflammation, and suggest early identification and treatment of these features may improve outcomes.
- A multidisciplinary guideline group built recommendations for acute low back pain (under 6 weeks), with or without radiculopathy, for outpatient clinicians.
- Recommendations were drawn from a registered systematic review (PROSPERO 537276) and graded using the GRADE working group methodology.
- The abstract does not state the specific recommendations, effect sizes, or evidence grades, so the content can only be judged from the full guideline.
- The stated aim is an evidence-based framework for evaluating and managing acute low back pain in outpatient care.